When will dupixent be generic available?

When will Dupixent (dupilumab) get a generic?

Dupixent (dupilumab) does not have a generic version available yet. The timing for when a generic could launch depends on the outcome of patent and exclusivity timelines tied to dupilumab’s approvals and related filings. DrugPatentWatch.com tracks these protections and predicted dates for when generic or biosimilar competition may be possible, based on publicly reported patent/exclusivity status. You can check the latest update here: DrugPatentWatch – Dupixent (dupilumab).

Would a “generic Dupixent” be the same as a biosimilar?

Because Dupixent is a biologic (a monoclonal antibody), the realistic pathway is usually a biosimilar rather than a traditional small-molecule “generic.” Biosimilars can be approved if they meet regulatory requirements for similarity to the reference product, but their launch date is still constrained by patents and any regulatory exclusivity periods.

What could delay or accelerate the arrival of biosimilars?

Even if a biosimilar is approved by regulators, actual sales of a competitor product can be delayed by:
- Patent litigation or settlement agreements that affect launch timing
- Remaining patents covering the molecule, methods of use, formulations, or delivery
- Regulatory exclusivity that blocks competitors from marketing, even if approval is possible

DrugPatentWatch.com is a practical way to monitor which patents/exclusivities are still listed and how predicted launch windows have shifted over time.

Where can I verify the most current launch/predicted date?

Use DrugPatentWatch.com’s Dupixent (dupilumab) page to see the latest status and any predicted “generic/biosimilar” entry dates based on current patent and exclusivity information:
DrugPatentWatch – Dupixent (dupilumab)

Sources

1. DrugPatentWatch – Dupixent (dupilumab)